

KLRC1 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP8629B

Product Information

| | |
|-------------------|------------------------|
| Application | WB, IHC-P, FC, IF, E |
| Primary Accession | P26715 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 26314 |
| Antigen Region | 180-206 |

Additional Information

| | |
|--------------------|--|
| Gene ID | 3821 |
| Other Names | NKG2-A/NKG2-B type II integral membrane protein, CD159 antigen-like family member A, NK cell receptor A, NKG2-A/B-activating NK receptor, CD159a, KLRC1, NKG2A |
| Target/Specificity | This KLRC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 180-206 amino acids from the C-terminal region of human KLRC1. |
| Dilution | WB~~1:2000 IHC-P~~1:100~500 FC~~1:25 IF~~1:25 E~~Use at an assay dependent concentration. |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | KLRC1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |

Protein Information

| | |
|----------|--|
| Name | KLRC1 |
| Synonyms | NKG2A {ECO:0000303 PubMed:18083576} |
| Function | Immune inhibitory receptor involved in self-nonsel self discrimination. In |

complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self (PubMed:[18083576](#), PubMed:[37264229](#), PubMed:[9430220](#), PubMed:[9486650](#)). Upon HLA-E-peptide binding, transmits intracellular signals through two immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHP-1 and INPPL1/SHP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules (PubMed:[12165520](#), PubMed:[9485206](#)). Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed:[30860984](#), PubMed:[9430220](#), PubMed:[9485206](#), PubMed:[9486650](#)). Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:[12387742](#)). On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFβ1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens (PubMed:[18064301](#)). In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion (PubMed:[30503213](#), PubMed:[30860984](#)).

Cellular Location

Cell membrane; Single-pass type II membrane protein

Tissue Location

Predominantly expressed in NK cells (at protein level) (PubMed:20952657, PubMed:9430220, PubMed:9485206). Expressed in intraepithelial CD8-positive T cell subsets with higher frequency in gamma-delta T cells than alpha-beta T cells (at protein level) (PubMed:18064301). Expressed in memory gamma-delta T cells (at protein level) (PubMed:20952657). Restricted to a subset of memory/effector CD8-positive alpha-beta T cells (at protein level) (PubMed:12387742) Expressed in intratumoral NK and CD8-positive T cells (PubMed:30503213). Expressed in melanoma-specific cytotoxic T cell clones (at protein level) (PubMed:9485206). KLRD1-KLRC1 and KLRD1-KLRC2 are differentially expressed in NK and T cell populations, with only minor subsets expressing both receptor complexes (at protein level) (PubMed:20952657).

Background


Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. This protein belongs to the killer cell lectin-like receptor family, also called NKG2 family, which is a group of transmembrane proteins preferentially expressed in NK cells. This family of proteins is characterized by the type II membrane orientation and the presence of a C-type lectin domain. This protein forms a complex with another family member, KLRD1/CD94, and has been implicated in the recognition of the MHC class I HLA-E molecules in NK cells.

References


Brooks,A.G., et.al., J. Exp. Med. 185 (4), 795-800 (1997)
Plougastel,B., et.al., Immunogenetics 44 (4), 286-291 (1996)

Images


Western blot analysis of KLRC1 Antibody (C-term) (Cat.




#AP8629b) in Jurkat cell line lysates (35ug/lane). KLRC1 (arrow) was detected using the purified Pab.



Formalin-fixed and paraffin-embedded human kidney carcinoma with KLRC1 Antibody (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



Flow cytometric analysis of jurkat cells using KLRC1 Antibody (C-term)(bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.



Confocal immunofluorescent analysis of KLRC1 Antibody (C-term)(Cat#AP8629b) with MDA-MB435 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.